Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

Barchart

FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary

The Department of Health and Human Services under Robert F

The Independent UK

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

International Business Times UK

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.

Benzinga

US experts fear all vaccines at risk as Trump officials target mRNA jabs

Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups

The Guardian - US

Read news from The Economist, FT, and more,
with one subscription

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Barchart

What you need to know about Moderna's new COVID vaccine, just approved by the FDA

The shot had previously been approved for everyone 12 and older. Now, there are limits.

Fortune

FDA approves Moderna's new lower-dose COVID-19 vaccine

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it

The Independent UK

HHS cancels funding for bird flu vaccine development because of RNA concerns

The Trump administration said the move signals a ‘shift in federal vaccine funding priorities’

The Independent UK

Moderna Loses $700M US Contract for Bird Flu Vaccine Development

Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.

International Business Times

Trump administration cancels $766 million Moderna contract to fight pandemic flu

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including H5N1 bird flu

The Independent UK

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

Barchart

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Fortune

This Moderna leader uses AI to resolve conflict on the executive team—all before it even happens

“I think I’m pretty good with people, but it gives me an advantage that I didn’t have before.”

LiveScience

2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayed

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

The Independent UK

Moderna study shows immune response in older adults for a combo flu and COVID-19 shot

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a company-funded study

The Conversation

From COVID to cancer: Why Canada’s RNA vaccine leadership matters more than ever

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.

The Independent UK

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax

International Business Times UK

Moderna Faces Suspension After Offering UK Children £1,500 And Teddy Bears To Join COVID Trials

Moderna, known for its COVID-19 vaccines, has been found guilty of 10 breaches of regulatory code after it marketed its booster jab trials towards children.

The Independent UK

Novavax says its COVID-19 shot is on track for full FDA approval after delay

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration

Barchart

What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

the Department of Health and Human Services

120 stories

US Food and Drug Administration

59 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.